Robust Automated Platform for Immunophenotyping Diagnostics (RAPID)

通过加拿大发明和制造生物技术的标准化和增强，这种多学科和协作的学术-行业合作伙伴关系旨在克服加拿大各地科学家和临床医生面临的生物医学挑战。通过促进在加拿大医院网络的小组织活检中使用高维组织病理学成像来分析免疫细胞，该项目有可能提升加拿大的医疗环境，以吸引国际临床试验和生物制药投资，并改善所有加拿大人的健康结果。高维组织病理学成像生物技术方法、单细胞分析的概率机器学习方法以及免疫图谱的临床应用方面的世界专家的共同努力，将创建一个强大的免疫诊断自动化管道，将在全国范围内共享。这一工具将在使用多重免疫细胞生物标记物的回顾、观察和协调研究中进行基准测试。与成像质量细胞仪制造商合作，图像采集、处理和机器学习分析方法的标准化和传播将创建一个能够提供加拿大尖端诊断的多中心网络。

Through the standardization and augmentation of Canadian invented and manufactured biotechnology, this multi-disciplinary and collaborative academic-industry partnership aims to overcome a biomedical challenge faced by scientists and clinicians across Canada. By facilitating the use of high-dimension histopathology imaging for immune cell profiling in small tissue biopsies across a network of Canadian hospitals, this project has the potential to elevate the Canadian healthcare environment in order to attract international clinical trials and biopharmaceutical investment and improve the health outcomes of all Canadians. The combined efforts of world experts in high dimension histopathology imaging biotechnology methods, probabilistic machine-learning methods for single cell analysis, and the clinical application of immune profiling will create of a robust automated pipeline for immune diagnostics which will be shared nationwide. This tool will be benchmarked in retrospective, observational and harmonization studies using multiplexed immune cell biomarkers. In concert with the manufacturer of imaging mass cytometry, the standardization and dissemination of image acquisition, processing, and machine learning analysis methods will create a multi-center network capable of providing access to cutting edge diagnostics in Canada.